43 Participants Needed

Plecanatide + Linaclotide for Digestive Health

Recruiting at 4 trial locations
SA
Overseen ByScott A. Waldman
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: University of Wisconsin, Madison
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.

Do I have to stop taking my current medications for this trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have taken plecanatide, linaclotide, or similar GCC agonists in the past week, and you should not be using other investigational agents within 12 weeks prior to registration.

What safety data exists for Plecanatide and Linaclotide?

Plecanatide and Linaclotide are used for treating chronic idiopathic constipation and irritable bowel syndrome with constipation. Linaclotide has been evaluated in several clinical trials, showing it is generally well tolerated, with diarrhea being the most common adverse effect. About 10% of patients discontinued Linaclotide due to gastrointestinal side effects, primarily diarrhea. There is no relevant safety data for Linaclotide during pregnancy. Plecanatide's safety profile is not detailed in the provided research, but it is used for similar conditions as Linaclotide.12345

Is the drug Linaclotide, Plecanatide a promising treatment for digestive health?

The information provided does not include any details about Linaclotide or Plecanatide, so we cannot determine if they are promising treatments for digestive health based on this data.678910

What data supports the idea that Plecanatide + Linaclotide for Digestive Health is an effective drug?

The available research does not provide specific data on the effectiveness of Plecanatide + Linaclotide for Digestive Health. Instead, it focuses on other treatments for pancreatic conditions, such as pancreatic enzyme replacement therapy, which has shown improvements in symptoms like diarrhea and pain in patients with pancreatic cancer. Therefore, no direct comparison or data on Plecanatide + Linaclotide is available in the provided information.1112131415

Who Is on the Research Team?

DS

David S. Weinberg

Principal Investigator

Fox Chase Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults over 18 who are not pregnant or breastfeeding, agree to use contraception, and have an ECOG performance status of <=1. They must be scheduled for an esophagogastroduodenoscopy (EGD), willing to provide biospecimens, and haven't used GCC agonists or investigational agents recently.

Inclusion Criteria

I am not pregnant or breastfeeding and agree to use contraception during the study.
I am on long-term antiviral treatment for herpes.
I am scheduled for an EGD procedure.
See 6 more

Exclusion Criteria

History of allergic reactions attributed to compounds of similar chemical or biologic composition of plecanatide or linaclotide
Use of any other investigational agents =< 12 weeks prior to registration
I have had weight loss surgery in the past.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single dose of plecanatide or linaclotide, or no drug, followed by standard of care EGD with biopsy and luminal fluid collection

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

7 days
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Linaclotide
  • Plecanatide
Trial Overview The study examines the effects of two FDA-approved constipation drugs, plecanatide or linaclotide, on a chemical in duodenal tissue from the small intestine compared to no drug treatment. Participants will undergo biospecimen collection including biopsy during EGD.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (linaclotide, EGD)Experimental Treatment4 Interventions
Group II: Arm I (plecanatide, EGD)Experimental Treatment4 Interventions
Group III: Arm III (EGD)Active Control3 Interventions

Linaclotide is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Linzess for:
🇪🇺
Approved in European Union as Constella for:
🇨🇦
Approved in Canada as Linzess for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Wisconsin, Madison

Lead Sponsor

Trials
1,249
Recruited
3,255,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

Pancreatic enzyme substitution is primarily indicated for malabsorption in chronic pancreatic insufficiency, which occurs when the pancreas has less than 2% of its exocrine secretory capacity, leading to significant fat malabsorption and diarrhea.
In some cases, pancreatic enzyme therapy may also help control pain in chronic pancreatitis, but the effectiveness depends on proper dosage, patient compliance, and the formulation of the enzyme preparation to withstand stomach acid.
Enzyme substitution in pancreatic disease.Andrén-Sandberg, A.[2018]
In a study of 95 patients with upper abdominal pain suggesting pancreatic disease, camostat mesilate significantly improved dyspeptic symptoms in those with suspected mild pancreatic disease and in an equivalent group, indicating its potential efficacy as a treatment.
The treatment involved administering 200 mg of camostat mesilate three times daily for 2 weeks, and symptom severity was measured using a visual analog scale, showing notable improvements in both the suspected pancreatic disease and equivalent groups.
Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease.Sai, JK., Suyama, M., Kubokawa, Y., et al.[2021]
Pancreatic enzyme replacement therapy is a safe and effective treatment for nutrient malabsorption due to pancreatic insufficiency, significantly reducing symptoms like steatorrhea and fat malabsorption.
Current challenges in treatment include ensuring enzymes reach the duodenum without being destroyed in the stomach, and research is focused on developing new enzymes and delivery systems to enhance treatment effectiveness.
Enzyme replacement therapy for pancreatic insufficiency: present and future.Fieker, A., Philpott, J., Armand, M.[2022]

Citations

Enzyme substitution in pancreatic disease. [2018]
Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. [2021]
Enzyme replacement therapy for pancreatic insufficiency: present and future. [2022]
The effectiveness of pancreatic enzyme replacement therapy for malabsorption in advanced pancreatic cancer, a pilot study. [2020]
5.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Use of Panzytrat in the replacement therapy of exocrine pancreatic insufficiency (an analytical review)]. [2007]
Plecanatide (Trulance) for Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. [2020]
Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic Constipation. [2022]
Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation. [2022]
Linaclotide. A bacterial enterotoxin derivative with a laxative action, nothing more. [2017]
Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity. [2019]
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]. [2015]
12.United Statespubmed.ncbi.nlm.nih.gov
Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. [2015]
Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. [2015]
Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability. [2020]
Linagliptin: an update of its use in patients with type 2 diabetes mellitus. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security